Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Trastuzumab and Paclitaxel in HER2+ Metastatic Breast Cancer
NCT01423695Phase 2Completed
- Sponsor
- Wisp
- Start
- Feb 2001
- Primary completion
- Dec 2009
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection and trastuzumab in breast cancer, sponsored by Wisp. Primary endpoint: Progression-free survival at 51 months. Started Feb 2001; status: completed.
02
Drugs
Paclitaxel Micelles for Injectiontrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01423695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01423695.